Mark Jacobson
Chief Operating Officer at AXSOME THERAPEUTICS, INC.
Net worth: - $ as of 2024-04-29
Mark Jacobson active positions
Companies | Position | Start | End |
---|---|---|---|
AXSOME THERAPEUTICS, INC. | Chief Operating Officer | 2014-03-31 | - |
Investor Relations Contact | 2014-03-31 | - | |
Corporate Secretary | 2015-09-30 | - |
Career history of Mark Jacobson
Former positions of Mark Jacobson
Companies | Position | Start | End |
---|---|---|---|
STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 2009-06-30 | 2014-02-28 |
Training of Mark Jacobson
Iowa State University | Undergraduate Degree |
The Trustees of Columbia University in The City of New York | Graduate Degree |
Statistics
International
United States | 5 |
Operational
Corporate Officer/Principal | 1 |
Undergraduate Degree | 1 |
Graduate Degree | 1 |
Sectoral
Health Technology | 3 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
AXSOME THERAPEUTICS, INC. | Health Technology |
Private companies | 1 |
---|---|
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Mark Jacobson
- Experience